Short Interest in Biotech Is Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Photo of Trey Thoelcke
By Trey Thoelcke Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The short interest in biotech stocks is mixed, judging by the short interest changes between the September 14 and September 28 settlement dates. There were notable swings in shares sold short from Biogen Idec, Celgene and Gilead Sciences. Short interest had largely risen in the previous period.

We have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Biogen Idec Inc. (NASDAQ: BIIB), Celgene Corp. (NASDAQ: CELG), Dendreon Corp. (NASDAQ: DNDN), Gilead Sciences Inc. (NASDAQ: GILD), Illumina Inc. (NASDAQ: ILMN), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), Pharmacyclics Inc. (NASDAQ: PCYC), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and VIVUS Inc. (NASDAQ: VVUS). We also tracked the iShares Nasdaq Biotechnology (NASDAQ: IBB) against the group.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest fell 6.3% between September 14 and September 28 to 5.03 million shares. Days to cover dropped to less than five.

Amgen Inc. (NASDAQ: AMGN) saw short interest tick up 0.6% to 12.69 million shares. But the average daily volume was the highest it has been since July.

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) short interest rose 4.4% to 47.69 million shares. That was the fourth consecutive increase. Short interest was 22.1% of the float.

Biogen Idec Inc. (NASDAQ: BIIB) shares sold short plunged almost 16% to 1.87 million, its lowest level this year. Days to cover declined to less than two. Short interest is less than 1% of the float.

Short interest in Celgene Corp. (NASDAQ: CELG) sank 18.8% to 4.91 million shares, its lowest level in a year. Days to cover fell to just under two.

Dendreon Corp. (NASDAQ: DNDN) short interest increased 6.4% to 45.83 million shares. This was 30.4% of the float. But days to cover dropped to less than nine from more than 11 in the previous period.

Gilead Sciences Inc. (NASDAQ: GILD) short interest jumped 26.3% to 26.05 million shares. Average daily volume was the highest it has been since February.

Illumina Inc. (NASDAQ: ILMN) saw short interest rise 7.7% to 27.75 million shares. That was the sixth consecutive period of increasing short interest. Short interest was 22.9% of the float.

Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) shares sold short increased 8.5% to 5.98 million. Days to cover fell to about three. Short interest was 9.3% of the float.

Pharmacyclics Inc. (NASDAQ: PCYC) short interest retreated 8.4% to 4.49 million shares. That was the lowest level this year. Short interest was 8.2% of the float.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) short interest fell about 4% to 4.98 million shares. Short interest was 6.7% of the float.

Short interest in Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) grew 9.4% to 7.08 million shares, its highest level since June. Days to cover is less than four.

VIVUS Inc. (NASDAQ: VVUS) short interest was down 5.4% to 15.19 million shares. Days to cover fell from about 10 in the previous period to less than four. Short interest was 15.2% of the float.

To show how the sector has held up: the iShares Nasdaq Biotechnology (NASDAQ: IBB) ETF closed at $142.59 on the same date. Its current 52-week range is $92.15 to $148.54.

Trey Thoelcke

Photo of Trey Thoelcke
About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618